All In Biotech

Drug Trial Radar · NCT05569954

Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)

A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older

Last checked: Nov 19, 2026Latest source record: Mar 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,484 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,484

Actual

Start

Nov 7, 2022

Primary completion

Oct 30, 2023

Study completion Feb 7, 2025

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Oct 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a phase 3, randomized, double-blind, active comparator-controlled study of the safety, tolerability, and immunogenicity of V116 in pneumococcal vaccine-naïve adults 50 years of age and older. The polyvalent (23-valent) pneumococcal vaccine, PPSV23, is the active comparator. In addition to studying safety/tolerability, it is hypothesized that, at 30 days postvaccination, the immunogenicity of V116 is noninferior to PPSV23 for the 12 common serotypes in V116 and PPSV23, and that V116 is superior to PPSV23 for the 9 serotypes unique to V116. It is also hypothesized that V116 is superior to PPSV23 in the percentage of participants with ≥4-fold rise from baseline in unique V116 serotypes, as measured by serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs).

Conditions

  • Pneumococcal Disease

Interventions

  • V116Biological

    Sterile 0.5 mL solution in prefilled syringe containing 4 μg of each pneumococcal polysaccharide (PnPs) antigen 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B.

  • PPSV23Biological

    Sterile 0.5 mL solution in prefilled syringe containing 25 μg of each PnPs antigen 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Solicited Injection-Site Adverse Events (AEs)Time frame: Up to 5 days postvaccination
  2. Percentage of Participants With Solicited Systemic AEsTime frame: Up to 5 days postvaccination
  3. Percentage of Participants With Vaccine-Related Serious Adverse Events (SAEs)Time frame: Up to 6 months postvaccination
  4. Serotype-Specific Opsonophagocytic (OPA) Geometric Mean Titers (GMTs) for All Serotypes in V116Time frame: Day 30 postvaccination
  5. Percentage of Participants With ≥4-fold Rise From Baseline in Serotype-Specific OPAs for Serotypes Unique to V116Time frame: Baseline (Day 1) and Day 30 postvaccination

Locations

55 sites in 11 countries. Site status is shown where the registry gives one.

  • Fundacion Estudios Clinicos ( Site 0200)

    Rosario, Santa Fe Province, Argentina

  • Paratus Clinical Research Western Sydney ( Site 1500)

    Blacktown, New South Wales, Australia

  • Northern Beaches Clinical Research ( Site 1502)

    Brookvale, New South Wales, Australia

  • Paratus Clinical Research Brisbane ( Site 1501)

    Albion, Queensland, Australia

  • IPS Centro Científico Asistencial S.A.S ( Site 0407)

    Barranquilla, Atlántico, Colombia

  • Fundacion Valle del Lili- CIC ( Site 0415)

    Cali, Valle del Cauca Department, Colombia

  • Universitaetsklinikum Hamburg-Eppendorf-Infektiologie ( Site 0901)

    Hamburg, Germany

  • klinikum rechts der isar der technischen universität münchen ( Site 0904)

    München, Bavaria, Germany

  • InfektioResearch ( Site 0903)

    Frankfurt am Main, Hesse, Germany

  • Universitaetsklinikum Koeln ( Site 0900)

    Cologne, North Rhine-Westphalia, Germany

  • Medizentrum Essen Borbeck ( Site 0902)

    Essen, North Rhine-Westphalia, Germany

  • Rambam Health Care Campus ( Site 1002)

    Haifa, Israel

  • Hadassah Medical Center-Clinical Reaserch Unit ( Site 1004)

    Jerusalem, Israel

  • Meir Medical Center-Infectious unit ( Site 1003)

    Kfar Saba, Israel

  • Sheba Medical Center ( Site 1000)

    Ramat Gan, Israel

  • Clalit Health Services - Sakhnin Community Clinic-Research Unit ( Site 1001)

    Sakhnin, Israel

  • Optimal Clinical Trials ( Site 1600)

    Auckland, New Zealand

  • P3 Research - Palmerston North ( Site 1602)

    Palmerston North, Manawatu-Wanganui, New Zealand

  • P3 Research - Lower Hutt ( Site 1601)

    Lower Hutt, Wellington Region, New Zealand

  • The Catholic University of Korea, Eunpyeong St. Mary's Hospital ( Site 1802)

    Seoul, South Korea

  • Asan Medical Center ( Site 1809)

    Seoul, South Korea

  • The Catholic Univ. of Korea Seoul St. Mary's Hospital ( Site 1806)

    Seoul, South Korea

  • Hallym University Kangnam Sacred Heart Hospital ( Site 1807)

    Seoul, South Korea

  • Ewha Womans University Mokdong Hospital-Infectious Diseases ( Site 1805)

    Seoul, South Korea

  • Korea University Guro Hospital ( Site 1800)

    Seoul, South Korea

  • Wonju Severance Christian Hospital ( Site 1808)

    Wŏnju, Kang-won-do, South Korea

  • Chonnam National University Hospital-Infectious Diseases ( Site 1811)

    Gwangju, Kwangju-Kwangyokshi, South Korea

  • Korea University Ansan Hospital ( Site 1801)

    Ansan-si, Kyonggi-do, South Korea

  • Soon Chun Hyang University Bucheon Hospital ( Site 1812)

    Bucheon-si, Kyonggi-do, South Korea

  • Hallym University Dongtan Sacred Heart Hospital ( Site 1813)

    Hwaseong-si, Kyonggi-do, South Korea

  • The Catholic University Of Korea St. Vincent's Hospital-Internal Medicine ( Site 1803)

    Suwon, Kyonggi-do, South Korea

  • Dong-A University Hospital ( Site 1810)

    Busan, Pusan-Kwangyokshi, South Korea

  • Kyungpook National University Chilgok Hospital-Division of Infectious Diseases ( Site 1804)

    Deagu, Taegu-Kwangyokshi, South Korea

  • Chungnam national university hospital ( Site 1814)

    Junggu, Taejon-Kwangyokshi, South Korea

  • Centre d'Atenció Primària Vallcarca - Sant Gervasi ( Site 1101)

    Barcelona, Spain

  • EAP Sardenya ( Site 1102)

    Barcelona, Spain

  • Hospital La Princesa-Clinical Pharmacology ( Site 1115)

    Madrid, Spain

  • EBA CENTELLES ( Site 1100)

    Centelles, Catalonia, Spain

  • Hospital Universitario Getafe ( Site 1111)

    Getafe, Madrid, Comunidad de, Spain

  • Fundación Oftalmologica del Mediterraneo-Vaccine Research ( Site 1118)

    Valencia, Valenciana, Comunitat, Spain

Showing 40 of 55 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.